Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about cholinesterase-inhibitors: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No summary available yet.
No AI portrait yet
| Neurovascular effects | ChEIs may improve cerebral blood flow through endothelial nitric oxide signaling. |
| ADAS-Cog improvement | Average 2.7-point improvement on the 70-point Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) relative to placebo. |
| MMSE stabilization | Approximately 1.5-point benefit on the Mini-Mental State Examination (MMSE) over 6-12 months. |
| Clinical meaningfulness | While the average effect size is modest, ~25-30% of patients show a clinically meaningful response (>4-point ADAS-Cog improvement), while others show minimal benefit. |
| Activities of daily living (ADLs) | ChEIs modestly slow functional decline, helping patients maintain independence in ADLs for several additional months. |
| Global clinical impression | Clinicians rate ChEI-treated patients as improved or stable more frequently than placebo-treated patients. |
| [mci](/diseases/mci) (MCI) | ChEIs have not demonstrated benefit in MCI and are not recommended for this indication. Multiple large trials (including the ADCS MCI trial) failed to show slowing of conversion from MCI to AD. |
| Mild to moderate AD | Primary indication. Most robust evidence of benefit, with treatment effects sustained for 6-12 months before cognitive decline resumes. |
| Severe AD | donepezil (10 mg and 23 mg) and rivastigmine patch are the only ChEIs with regulatory approval for severe AD. Benefits include stabilization of functional abilities and reduced caregiver burden. |
| Approval | 1996 (FDA); mild to moderate and severe AD |
| Dosing | 5 mg/day initially, increased to 10 mg/day; 23 mg/day available for moderate-severe |
| Half-life | ~70 hours (allows once-daily dosing) |
| Databases | OMIMOrphanetClinicalTrialsPubMed |
Knowledge base pages for this entity
flowchart TD
N0["Cholinesterase Inhibitors"]
N1["Dementia"]
N0 -->|"treats"| N1
N2["Alzheimer'S Disease"]
N0 -->|"treats"| N2
N3["Mild Dementia"]
N0 -->|"treats"| N3
N4["Alzheimer's Disease"]
N0 -->|"treats"| N4
N5["Functional Stabilization"]
N0 -->|"promotes"| N5
classDef gene fill:#1a3a2a,stroke:#4caf50,color:#e0e0e0
classDef protein fill:#1a2a3a,stroke:#4fc3f7,color:#e0e0e0
classDef disease fill:#3a1a1a,stroke:#ef5350,color:#e0e0e0
classDef pathway fill:#2a1a3a,stroke:#ce93d8,color:#e0e0e0
classDef mechanism fill:#2a2a1a,stroke:#ffd54f,color:#e0e0e0
classDef therapeutic fill:#1a2a2a,stroke:#26a69a,color:#e0e0e0
class N1 disease
class N2 disease
class N3 disease
class N4 disease| Target | Relation | Type | Str |
|---|---|---|---|
| No outgoing edges | |||
| Source | Relation | Type | Str |
|---|---|---|---|
| No incoming edges | |||
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| No targeting hypotheses | |||
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| No experiments found | |||||||
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| No papers found | ||||
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning cholinesterase-inhibitors in their description or question text
No additional research found